Insilico Medicine, an AI-based drug developer, has made significant strides with its lead candidate, ISM001-055, in the treatment of idiopathic pulmonary fibrosis (IPF). Following promising results from a Phase IIa trial, the company is now gearing up for potentially pivotal clinical trials that
Imagine a common over-the-counter pain reliever having the potential to alleviate the symptoms of a rare genetic disorder that currently lacks any formal treatment. This possibility could mark a significant breakthrough for patients who face enormous challenges and discomfort due to their
The global cell culture vessels market is on a remarkable growth trajectory, projected to expand from an estimated USD 4.90 billion in 2023 to over USD 19.65 billion by 2033. This significant growth, at a robust CAGR of 14.9% from 2024 to 2033, underscores the critical role of cell culture
The biopharma industry, renowned for its rapid innovation and significant contributions to healthcare, currently faces a tumultuous period marked by widespread layoffs. From early 2023 through late 2024, numerous companies have announced substantial workforce reductions, which reflect a time of
Urticaria, commonly known as hives, is a prevalent skin condition affecting up to 20% of the global population at some point in their lives, causing a significant impact on individuals' quality of life. It is characterized by the rapid appearance of raised, itchy welts or wheals on the skin
Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to
In the ever-evolving landscape of biopharmaceuticals, companies face the immense challenge of managing regulated data and documents, which has become more complex due to the surge in global regulations. The increasing necessity for a unified Regulatory Information Management (RIM) solution that
Recent developments and analyst perspectives have spotlighted Arbutus Biopharma (NASDAQ: ABUS), indicating a promising growth trajectory for this biopharmaceutical company. Chardan Capital's recent decision to raise its target price for Arbutus Biopharma from $4.00 to $4.50 signifies a
Biopharmaceutical fermentation systems are at the forefront of modern medicine, playing a crucial role in the production of biological drugs such as therapeutic proteins, enzymes, monoclonal antibodies, and vaccines. These systems are designed to cultivate microorganisms or cells in controlled
In recent developments, Celltrion USA has significantly expanded the availability of its subcutaneous treatment for Crohn's disease and ulcerative colitis, Zymfentra, now accessible to 26 million patients across the United States. This milestone achievement is a result of the company’s s
